癌症免疫疗法
免疫疗法
抗体
融合蛋白
白细胞介素2
CD8型
白细胞介素15
免疫学
生物
化学
免疫系统
生物化学
细胞因子
白细胞介素
重组DNA
基因
作者
Patrizia Murer,Barbara Brannetti,Jean‐Michel Rondeau,Laetitia Petersen,Nicole Egli,Simone L. Popp,Catherine H. Régnier,Kirsten Richter,Andreas Katopodis,Christoph Huber
出处
期刊:mAbs
[Informa]
日期:2024-07-23
卷期号:16 (1)
标识
DOI:10.1080/19420862.2024.2381891
摘要
Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 antibody fusion protein designed for selective IL-2 receptor βγ (IL-2 Rβγ) activation by sterically hindering IL-2 from binding to IL-2 Rα. The fusion protein has an IL-2 connected to the light chain complementarity-determining region (CDR) domain of a humanized antibody that binds to IL-2 at the same epitope as IL-2 Rα. Optimization of the selectivity and pharmacological properties led to the selection of ANV419. ANV419 preferentially expands CD8
科研通智能强力驱动
Strongly Powered by AbleSci AI